Agilent Technologies Reports Second Quarter Fiscal Year 2019 Financial Results

Highlights:

Revenue of $1.24 billion represents 3 percent reported growth and 4 percent core revenue⁽¹⁾ growth
GAAP net income of $182 million and EPS of $0.57
Non-GAAP net income of $228 million or $0.71 per share⁽²⁾, up 9 percent year-over-year
Full-year revenue outlook revised to $5.085 billion to $5.125 billion, with non-GAAP earnings guidance for the year maintained at $3.03 to $3.07 per share⁽³⁾

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2019, up 3 percent year-over-year (up 4 percent on a core basis⁽¹⁾).

On a GAAP basis, second-quarter net income was $182 million or $0.57 per share. This compares with $205 million and $0.63 per share in the second quarter of 2018. Non-GAAP net income⁽²⁾ was $228 million or $0.71 per share during the quarter, compared with $212 million and $0.65 per share during the second quarter a year ago.

"While overall revenues were below our expectations, the story of our second quarter results is one where we demonstrated the resilience of Agilent's business model," said Mike McMullen, Agilent president and CEO. "Two of our three business units continued to deliver strong growth while the third was affected by soft market conditions. We generated EPS of $0.71, representing 9 percent growth, which was at the midpoint of our guidance."

Financial Highlights

Life Sciences and Applied Markets Group

Second-quarter revenue of $529 million from Agilent's Life Sciences and Applied Markets Group (LSAG) was down 1 percent year over year (down 1 percent on a core basis⁽¹⁾). Demand in the environmental and forensics markets was strong, offset by weakness in the pharma and food markets. LSAG's operating margin for the quarter was 20.3 percent.

Agilent CrossLab Group

Second-quarter revenue of $455 million from the Agilent CrossLab Group (ACG) grew 7 percent year over year (up 9 percent on a core basis⁽¹⁾). Growth was broad-based across all regions, led by China. ACG's operating margin for the quarter was 25.2 percent.

Diagnostics and Genomics Group

Second-quarter revenue of $254 million from Agilent's Diagnostics and Genomics Group (DGG) grew 5 percent year over year (up 6 percent on a core basis⁽¹⁾). Strength in the company's pathology-related businesses and NASD led the group's results. DGG's operating margin for the quarter was 19.3 percent.

Third-Quarter and Full-Year Outlook

Agilent expects third-quarter 2019 revenue in the range of $1.225 billion to $1.245 billion. Third-quarter 2019 non-GAAP earnings are expected to be in the range of $0.71 to $0.73 per share⁽³⁾.

For fiscal year 2019, the company is revising its full-year revenue guidance to a range of $5.085 billion to $5.125 billion while maintaining non-GAAP earnings guidance in the range of $3.03 to $3.07 per share⁽³⁾.

Conference Call

Agilent's management will present more details about its second-quarter fiscal year 2019 financial results on a conference call with investors today at 1:30 p.m. (Pacific Time). This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select "Q2 2019 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events — Calendar of Events" section. The webcast will remain available on the company's website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting "Financial Results" in the "Financial Information" section.

A telephone replay of the conference call will be available at approximately 4:30 p.m. (Pacific Time) after the call on May 14 and through May 21 by dialing (855) 859-2056 (or (404) 537-3406 from outside the United States) and entering passcode 3086626.

# # #

Financial Statements for Second-Quarter Fiscal 2019


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY


	Three Months Ended						Six Months Ended
	April 30,						April 30,
	2019			2018^(a)			2019			2018^(a)

Net revenue	$	1,238		$	1,206		$	2,522		$	2,417

Costs and expenses:
Cost of products and services		569			563			1,146			1,104
Research and development		99			92			201			186
Selling, general and administrative		354			341			709			688
Total costs and expenses		1,022			996			2,056			1,978

Income from operations		216			210			466			439

Interest income		10			10			20			19
Interest expense		(17	)		(19	)		(35	)		(39	)
Other income (expense), net		9			26			15			41

Income before taxes		218			227			466			460

Provision for (benefit from) income taxes		36			22			(220	)		575

Net income (loss)	$	182		$	205		$	686		$	(115	)



Net income (loss) per share:
Basic	$	0.57		$	0.64		$	2.16		$	(0.36	)
Diluted	$	0.57		$	0.63		$	2.13		$	(0.36	)

Weighted average shares used in computing net income (loss) per share:
Basic		317			322			318			323
Diluted		321			326			322			323





^(a) Adjusted to include the impact of the adoption of ASU 2017-07 (pension expense reclassification) as of 11/1/2018. There is no impact to net income (loss) or net income (loss) per share.


The preliminary income statement is estimated based on our current information.


Page 1


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY


	April 30,			October 31,
	2019			2018
ASSETS

Current assets:
Cash and cash equivalents	$	2,155		$	2,247
Accounts receivable, net		819			776
Inventory		657			638
Other current assets		181			187
Total current assets		3,812			3,848

Property, plant and equipment, net		827			822
Goodwill and other intangible assets, net		3,650			3,464
Long-term investments		96			68
Other assets		637			339
Total assets	$	9,022		$	8,541

LIABILITIES AND EQUITY

Current liabilities:
Accounts payable	$	314		$	340
Employee compensation and benefits		292			304
Deferred revenue		347			324
Other accrued liabilities		165			203
Total current liabilities		1,118			1,171

Long-term debt		1,798			1,799
Retirement and post-retirement benefits		229			239
Other long-term liabilities		752			761
Total liabilities		3,897			3,970

Total Equity:
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding		—			—
Common stock; $0.01 par value, 2 billion shares authorized; 317 million shares at April 30, 2019 and 318 million shares at October 31, 2018, issued		3			3
Treasury stock at cost; 9 thousand shares at April 30, 2019 and zero shares at October 31, 2018		(1	)		—
Additional paid-in-capital		5,343			5,308
Retained earnings (accumulated deficit)		178			(336	)
Accumulated other comprehensive loss		(398	)		(408	)
Total stockholders' equity		5,125			4,567
Non-controlling interest		—			4
Total equity		5,125			4,571
Total liabilities and equity	$	9,022		$	8,541



The preliminary balance sheet is estimated based on our current information.


Page 2


AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY


	Six Months Ended
	April 30,			April 30,
	2019			2018
Cash flows from operating activities:
Net income (loss)	$	686		$	(115	)

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		107			101
Share-based compensation		40			43
Excess and obsolete inventory related charges		7			17
Other non-cash expenses, net		2			2
Changes in assets and liabilities:
Accounts receivable, net		(17	)		(21	)
Inventory		(21	)		(34	)
Accounts payable		(8	)		(14	)
Employee compensation and benefits		(13	)		(7	)
Change in assets and liabilities due to Tax Act		—			533
Other assets and liabilities		(318	)		13
Net cash provided by operating activities ^(a)		465			518

Cash flows from investing activities:
Investments in property, plant and equipment		(78	)		(108	)
Payment to acquire fair value investments		(18	)		(1	)
Payment in exchange for convertible note		(2	)		(2	)
Acquisition of businesses and intangible assets, net of cash acquired		(248	)		(7	)
Net cash used in investing activities		(346	)		(118	)

Cash flows from financing activities:
Issuance of common stock under employee stock plans		33			36
Payment of taxes related to net share settlement of equity awards		(14	)		(29	)
Payment of dividends		(104	)		(96	)
Proceeds from revolving credit facility		—			356
Repayment of debt and revolving credit facility		—			(251	)
Purchase of non-controlling interest		(4	)		—
Treasury stock repurchases		(125	)		(93	)
Net cash used in financing activities		(214	)		(77	)

Effect of exchange rate movements		2			9

Net increase (decrease) in cash, cash equivalents and restricted cash		(93	)		332

Cash, cash equivalents and restricted cash at beginning of period		2,254			2,686

Cash, cash equivalents and restricted cash at end of period	$	2,161		$	3,018


Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:

Cash and cash equivalents	$	2,155		$	3,011
Restricted cash, included in other assets		6			7
Total cash, cash equivalents and restricted cash	$	2,161		$	3,018


^(a) Cash payments included in operating activities:

Income tax payments (refunds), net	$	104		$	48
Interest payments	$	36		$	43



The preliminary cash flow is estimated based on our current information.


Page 3


AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY

	Three Months Ended				Six Months Ended
	April 30,				April 30,
	2019	Diluted EPS	2018	Diluted EPS	2019	Diluted EPS	2018	Diluted EPS

GAAP net income (loss)	$ 182	$ 0.57	$ 205	$ 0.63	$ 686	$ 2.13	$ (115)	$ (0.36)	^(b)
Non-GAAP adjustments:
Intangible amortization	26	0.08	25	0.08	54	0.17	50	0.15
Business exit and divestiture costs	—	—	8	0.02	—	—	8	0.02
Transformational initiatives	9	0.03	5	0.02	14	0.04	9	0.03
Acquisition and integration costs	10	0.03	4	0.01	20	0.06	7	0.02
Pension settlement gain	—	—	—	—	—	—	(5)	(0.02)
NASD site costs	4	0.01	2	0.01	6	0.02	4	0.01
Special compliance costs	1	—	1	—	1	—	2	0.01
Other	5	0.02	(14)	(0.04)	6	0.02	(13)	(0.04)
Adjustment for Tax Reform	—	—	—	—	—	—	533	1.63
Tax benefit on intra-entity asset transfer	—	—	—	—	(299)	(0.93)	—	—
Adjustment for taxes ^(a)	(9)	(0.03)	(24)	(0.08)	(16)	(0.04)	(52)	(0.14)
Non-GAAP net income	$ 228	$ 0.71	$ 212	$ 0.65	$ 472	$ 1.47	$ 428	$ 1.31	^(c)


^(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three months ended April 30, 2019, management used a non-GAAP effective tax rate of 16.48%. For the six months ended April 30, 2019, management used a non-GAAP effective tax rate of 16.75%. In the same periods last year, management used a non-GAAP effective tax rate of 18%.

^(b) GAAP diluted net loss per share was computed using 323 million weighted average diluted shares which excludes from consideration the anti-dilutive effects of all potential common shares outstanding.

^(c) Non-GAAP diluted net income per share was computed using 326 million weighted average diluted shares which includes the dilutive effects of potential common shares outstanding.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, pension settlement gain, NASD site costs, special compliance costs, adjustment for Tax Reform, and tax benefit on intra-entity asset transfer.

Business exit and divestiture costs include costs associated with business divestitures.

Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing due to new tariffs and tariff remediation actions, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.

Acquisition and Integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

Pension settlement gain resulted from transfer of the substitutional portion of our Japanese pension plan to the government.

NASD site costs include all the costs related to the expansion of our manufacturing of nucleic acid active pharmaceutical ingredients incurred prior to the commencement of commercial manufacturing.

Special compliance costs include costs associated with transforming our processes to implement new regulations such as the EU's General Data Protection Regulation (GDPR), revenue recognition and certain tax reporting requirements.

Other includes certain legal costs and settlements in addition to other miscellaneous adjustments.

Adjustment for Tax Reform primarily consists of an estimated provision of $480 million for U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and an estimated provision of $53 million associated with the decrease in the U.S. corporate tax rate from 35% to 21% and its impact on our U.S. deferred tax assets and liabilities. The taxes payable associated with the transition tax, net of tax attributes, on deemed repatriation of foreign earnings is approximately $440 million, payable over 8 years.

Tax benefit on intra-entity asset transfer relates to our operations in Singapore along with our application of the new accounting rules for income tax consequences of intra-entity transfer of assets as adopted on November 1, 2018.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.


Page 4


AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY

Life Sciences and Applied Markets Group
	Q2'19			Q2'18
Revenue	$	529		$	537
Gross Margin, %		60.6	%		59.7	%
Income from Operations	$	107		$	113
Operating margin, %		20.3	%		21.0	%


Diagnostics and Genomics Group
	Q2'19			Q2'18
Revenue	$	254		$	243
Gross Margin, %		54.8	%		54.8	%
Income from Operations	$	49		$	48
Operating margin, %		19.3	%		19.9	%


Agilent CrossLab Group
	Q2'19			Q2'18
Revenue	$	455		$	426
Gross Margin, %		51.3	%		50.0	%
Income from Operations	$	115		$	96
Operating margin, %		25.2	%		22.5	%






Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, pension settlement gain, NASD site costs, and special compliance costs.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.


Page 5


AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY SEGMENT EXCLUDING
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY

	Year-over-Year

	GAAP
			Year-over-Year
GAAP Revenue by Segment	Q2'19	Q2'18	% Change

Life Sciences and Applied Markets Group	$ 529	$ 537	(1%)

Diagnostics and Genomics Group	254	243	5%

Agilent CrossLab Group	455	426	7%

Agilent	$ 1,238	$ 1,206	3%




	Non-GAAP (excluding Acquisitions & Divestitures)			Year-over-Year at Constant Currency ^(a)
			Year-over-Year	Year-over-Year	Percentage Point Impact	Current Quarter Currency
Non GAAP Revenue by Segment	Q2'19	Q2'18	% Change	% Change	from Currency	Impact^(b)

Life Sciences and Applied Markets Group	$ 519	$ 537	(3%)	(1%)	-2 ppts	$ (12)

Diagnostics and Genomics Group	248	243	2%	6%	-4 ppts	(8)

Agilent CrossLab Group	448	426	5%	9%	-4 ppts	(18)

Agilent (Core)	$ 1,215	$ 1,206	1%	4%	-3 ppts	$ (38)



We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

^(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter, and then using those revised values to calculate the year-over-year percentage change.

^(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.





Page 6

Download Financial Statements for Second-Quarter Fiscal 2019

Financial Tables (156KB)

Newsroom

Press Release